Skip to main content

Table 2 Characteristics of patients in included trials

From: Safety, efficacy and biomarkers analysis of mesenchymal stromal cells therapy in ARDS: a systematic review and meta-analysis based on phase I and II RCTs

Trail (Study ID) Country Study type The number of patients, n Age, year
(mean/mean ± SD)
Male sex, n(%)
MSC Ctrl Total MSC Ctr
Monsel et al. [22] France Phase 2b RCT 21 24 45 64 ± 10.4 63.2 ± 11.4 37(82.2%)
Bellingan et al. [21] UK Phase 2a trial RCT 20 10 30 51 ± 14 59 ± 18 19 (63.3%)
Lanzoni et al. [20] USA Phase 1/2a trial RCT 12 12 24 58.6 ± 15.9 58.8 ± 11.6 13 (54.2%)
Matthay et al. [19] USA Phase 2a trial RCT 40 20 60 55 ± 17 55 ± 20 33 (55%)
Zheng et al. [18] China phase 1 trial RCT 6 6 12 66.7 ± 20.4 69.8 ± 9.1 11(91.7%)
Trail (Study ID) PaO2/FiO2, mmHg
(mean ± SD)/ median (IQR)
SOFA score
(mean ± SD)
Primary ARDS Cause Lung Injury Score (mean ± SD)
MSC Ctrl MSC Ctrl MSC Ctrl
Monsel et al. [22] 156.2 ± 68.2 171.2 ± 72.9 5.5 ± 2.7 5.9 ± 2.7 COVID-19 3.0 ± 0.7 2.8 ± 0.5
Bellingan et al. [21] 173 ± 56.4 128 ± 35.1 10.9 ± 2.2a 12.2 ± 4.2a Pneumonia NR NR
Lanzoni et al. [20] 124
(68–164)b
108.5
(68.5–165.5)b
NR NR COVID-19 NR NR
Matthay et al. [19] 135.8 ± 32.3 143.3 ± 39 8.1 ± 3.3 6.9 ± 2.7 Pneumonia 3.1 ± 0.4 3.0 ± 0.5
Zheng et al. [18] 122.4 ± 42 103.5 ± 32.2 NR NR Pneumonia NR NR
  1. aModified SOFA, For SOFA scoring, all patients were assigned a nervous system domain score + 4 = Glasgow Coma Score (GCS) < 6
  2. bPaO2/FiO2: median (IQR)
  3. RCT Randomized Controlled Trial, MSC Mesenchymal stromal cell group, Ctrl Control group, NR not reported